Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Liquidity [Abstract]
Accumulated deficit	$ 147,033		$ 196,321
Shareholders' equity	$ 189,697		$ 130,508
Reclassifications from subscription and advertisement revenues to royalties		$ 77
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares)	107,384	90,421
Asterias Biotherapeutics and OncoCyte [Member]
Liquidity [Abstract]
Cash and cash equivalents, available for sale securities, combined value	$ 161,300
Parent [Member]
Liquidity [Abstract]
Accumulated deficit	(147,000)
Working capital	20,400
Shareholders' equity	190,000
Cash, cash equivalents and available for sale securities	$ 24,700
Treasury Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares)	330,000
Anti-dilutive shares excluded from computation of diluted income (loss) per share (in shares)	0	4,473,000
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares)	342,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares)	342,000
Anti-dilutive shares excluded from computation of diluted income (loss) per share (in shares)	4,701,000	5,454,000
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from computation of diluted income (loss) per share (in shares)	9,395,000	9,395,000